-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Bijing Quan
Bijing QuanDeputy Director of the Economic Committee of the National Committee of the Chinese People's Political Consultative Conference
Executive Vice Chairman of China Center for International Economic Exchanges
"Biomedicine is one of
the fields with the highest scientific and technological content, the most intensive innovation and the most active investment in the new round of scientific and technological change in the world.
In the past decade, China has made significant achievements in the field of biomedical innovation, with the number of new drugs approved for marketing in China accounting for about 15% of the world, the number of new drugs under research by local companies accounting for 33% of the world, and more than
5,500 new drug clinical trials in China.
The innovation of biomedicine has become one of the important symbols of China's entry into an innovation-oriented country.
"
On November 5, Bi Jingquan, deputy director of the Economic Committee of the National Committee of the Chinese People's Political Consultative Conference and executive vice chairman of the China Center for International Economic Exchanges, pointed out
at the sub-forum of the Fifth Hongqiao International Economic Forum.
Bi Jingquan believes that to promote the high-quality development of the pharmaceutical and health industry, more original scientific discoveries
are needed.
While we see the achievements, we must also see the shortcomings, in recent years, most of the innovative drugs approved for marketing belong to follow-up, introduction innovation, new targets, new compounds, new mechanisms of action of the original new drugs are not many, the quality of innovation and the world's advanced level there is still a gap, we very much need artemisinin, arsenic trioxide and all-trans retinoic acid treatment of leukemia, hepatitis B virus into the human cell target such original scientific discoveries, based on these original scientific discoveries of research and development, More original treatments will surely be born
.
"China's development of biomedicine has many advantages
.
Our country has a large population, rapid development and a large market scale, so we must promote the coordinated development and governance of medical insurance, medical treatment and medicine",
Bi Jingquan put forward the following suggestions for improving the development quality of the biomedical industry:
in developing biomedicine.
Our country has a large population, rapid development and a large market scale, so we must promote the coordinated development and governance of medical insurance, medical treatment and medicine
First, encourage original research and development, and encourage the launch
of drugs with better clinical value.
In 2021, the National Center for Drug Evaluation issued the Guidelines for Clinical Research and Development of Clinical Value-oriented Antitumor Drugs, which proposed that subjects should be provided with the best treatment methods/drugs in clinical practice as much as possible, and new drug research and development should provide patients with more clinically valuable treatment options as the highest goal
.
These requirements should become universally applicable guiding principles
for drug research and development.
Measures should be taken to encourage the listing and use of innovative drugs with original originality and better clinical value from the aspects of review and approval, clinical use, and medical insurance payment, and encourage the discovery of original achievements
with high value from the treasure trove of traditional Chinese medicine.
For the indications of existing treatment methods, new drug research and development enterprises should be encouraged to develop new drugs
with more clinical value.
of drugs with better clinical value.
Second, improve the level and efficiency
of supervision.
To promote the high-quality development of the biopharmaceutical industry, it is necessary to benchmark with international practices and best practices from all aspects of the whole life cycle of drug research and development, identify gaps, improve policies, improve efficiency and transparency, provide scientists and enterprises with more efficient and predictable services, and improve the international competitiveness
of pharmaceutical research and development.
of supervision.
Third, enable patients to use the best treatment drugs
.
Medical institutions are encouraged to purchase new drugs approved for marketing in a timely manner, without being restricted
by the number of drugs used in hospitals.
At present, there are only dozens of new drugs approved for marketing every year, which will not pose any pressure on the increase in the number of drugs used by medical institutions, and it is recommended to adjust the relevant regulations
.
.
Fourth, stabilize the market expectations of
innovative drugs.
Stabilizing market expectations is essential
for continued drug development.
Capital will flow from areas with poor expectations to areas with good expectations, which is the concrete embodiment
of the decisive role of the market in the allocation of resources.
The price formation mechanism of innovative drugs directly affects the market expectations of
enterprises.
New drug research and development is a high-risk business, how much can be sold after the new drug is launched, whether the sales revenue can cover the cost of research and development, whether there can be profits to invest in new research and development, these are still left to the company itself to explore
.
For high-priced innovative drugs, medical insurance determines the payment standard
according to the financial situation.
innovative drugs.
Fifth, develop high-quality generic drugs
.
The fundamental measure to address access to medicines is the development of generic drugs
.
It is necessary to continue to encourage enterprises to carry out consistency evaluation of generic drugs, implement relevant incentive policies, curb vicious competition, and ensure the quality and supply
of winning drugs.
It is necessary to clarify the exit policy of drug document numbers that have not passed the consistency evaluation, and study the annual supervision fee charged according to the drug document number, forcing zombie document numbers that have not been produced for many years to withdraw from the market and reduce regulatory pressure
.
.
Sixth, standardize the development of
commercial medical insurance.
The key to establishing a multi-level medical security system is to draw the boundary between basic medical insurance and commercial medical insurance, clarify the market scope of commercial medical insurance, facilitate the actuarial calculation of insurance companies, and launch commercial insurance products with clear coverage to facilitate consumers to apply for insurance and facilitate social supervision
.
It is necessary to clarify the principle of balanced income and expenditure and slight balance of commercial medical insurance, encourage competition among commercial medical insurance companies, improve the efficiency of claims settlement, and provide high-quality medical security services
for policyholders.
commercial medical insurance.
Seventh, reform the compensation mechanism
of medical institutions.
In accordance with the principle of "total quantity control and structural adjustment" and on the premise of not increasing the total burden of medical expenses in society, we should gradually straighten out the prices of medical services and realize that medical service charges cover all the salary expenditures of medical personnel
.
Promote a unified electronic medical record and electronic prescription system shared by medical institutions and medical insurance institutions, promote rational drug use, realize the sharing of examination and test results, reduce doctors' duplication of work, improve diagnosis and efficacy rates, reduce prescription errors, and improve the diagnosis and treatment level of
grassroots doctors.
Only by realizing the reform of separating medicine can drugs return to their own attributes
.
of medical institutions.
Eighth, increase investment in
basic research.
Without strong basic research, it is difficult to produce original scientific research results
.
It is recommended to increase the funding of basic research in the field of life sciences, reform the evaluation methods of scientific and technological achievements, implement the provisions of the Law on Promoting the Transformation of Scientific and Technological Achievements and the Law on Scientific and Technological Progress that reward scientific researchers with no less than 50% of the net income from the transformation of scientific and technological achievements, and encourage scientists to invent and create
.
basic research.
Ninth, expand international cooperation
in the field of biomedicine.
It is necessary to further expand the institutional opening up of the biomedical field, participate more in the formulation and adoption of international drug research and development guidelines, and minimize the institutional costs
of the development of the biomedical industry.
Strengthen the exchange of public health and medical information in
the international community.
"The new crown vaccine developed by China has contributed
to the fight against the epidemic in many countries.
in the field of biomedicine.
Although China's biomedical innovation has just started, the anti-cancer drugs developed are inexpensive and can fully benefit patients in the Asia-Pacific region and the 'Belt and Road' developing countries.
"
Bi Jingquan said
.
